

Peter Bolli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3581261/publications.pdf>

Version: 2024-02-01

64
papers

5,548
citations

126907

33
h-index

123424

61
g-index

66
all docs

66
docs citations

66
times ranked

4490
citing authors

#	ARTICLE	IF	CITATIONS
1	Atrial Natriuretic Peptide and Atrial Pressure in Patients with Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1986, 315, 533-537.	27.0	622
2	Correlation of Platelet Calcium with Blood Pressure. <i>New England Journal of Medicine</i> , 1984, 310, 1084-1088.	27.0	556
3	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2018, 34, 506-525.	1.7	474
4	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 549-568.	1.7	431
5	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2016, 32, 569-588.	1.7	400
6	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020, 36, 596-624.	1.7	324
7	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. <i>Canadian Journal of Cardiology</i> , 2017, 33, 557-576.	1.7	269
8	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 485-501.	1.7	221
9	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. <i>Canadian Journal of Cardiology</i> , 2012, 28, 270-287.	1.7	173
10	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I " blood pressure measurement, diagnosis and assessment of risk. <i>Canadian Journal of Cardiology</i> , 2010, 26, 241-248.	1.7	170
11	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2013, 29, 528-542.	1.7	163
12	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. <i>Canadian Journal of Cardiology</i> , 2011, 27, 415-433.e2.	1.7	127
13	Renin Profiling to Select Anti hypertensive Baseline Drugs. <i>American Journal of Medicine</i> , 1984, 77, 36-42.	1.5	98
14	Age, race, blood pressure and renin: Predictors for antihypertensive treatment with calcium antagonists. <i>American Journal of Cardiology</i> , 1985, 56, H81-H85.	1.6	95
15	A New Algorithm for the Diagnosis of Hypertension in Canada. <i>Canadian Journal of Cardiology</i> , 2015, 31, 620-630.	1.7	88
16	Greater Antihypertensive Efficacy of the Calcium Channel Inhibitor Verapamil in Older and Low Renin Patients. <i>Clinical Science</i> , 1982, 63, 439s-442s.	0.0	84
17	The Role of Adiponectin in Endothelial Dysfunction and Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 463.	3.5	77
18	Antihypertensive Treatment Using Calcium Antagonists in Combination with Captopril Rather than Diuretics. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, S88-S91.	1.9	72

#	ARTICLE	IF	CITATIONS
19	Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. <i>Journal of the American College of Cardiology</i> , 1986, 7, 344-348.	2.8	64
20	Plasma Catecholamines and Cardiac, Renal and Peripheral Vascular Adrenoceptor-Mediated Responses in Different Age Groups of Normal and Hypertensive Subjects. <i>Clinical and Experimental Hypertension</i> , 1980, 2, 409-426.	1.3	62
21	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. <i>Canadian Journal of Cardiology</i> , 2005, 21, 645-56.	1.7	61
22	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 " blood pressure measurement, diagnosis and assessment of risk. <i>Canadian Journal of Cardiology</i> , 2009, 25, 279-286.	1.7	60
23	New Algorithm for the Diagnosis of Hypertension Canadian Hypertension Education Program Recommendations (2005). <i>American Journal of Hypertension</i> , 2005, 18, 1369-1374.	2.0	57
24	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I " Blood pressure measurement, diagnosis and assessment of risk. <i>Canadian Journal of Cardiology</i> , 2006, 22, 573-581.	1.7	56
25	Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension. <i>American Heart Journal</i> , 1988, 115, 282-288.	2.7	52
26	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 " blood pressure measurement, diagnosis and assessment of risk. <i>Canadian Journal of Cardiology</i> , 2007, 23, 529-538.	1.7	49
27	Calcium antagonists and the second drug for hypertensive therapy. <i>American Journal of Medicine</i> , 1986, 81, 25-29.	1.5	47
28	Parallel Reduction of Calcium-Influx-Dependent Vasoconstriction and Platelet-Free Calcium Concentration with Calcium Entry and α_1 -Adrenoceptor Blockade. <i>Journal of Cardiovascular Pharmacology</i> , 1984, 6, S1002.	1.9	43
29	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 " blood pressure measurement, diagnosis and assessment of risk. <i>Canadian Journal of Cardiology</i> , 2008, 24, 455-463.	1.7	38
30	The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I–Blood pressure measurement, diagnosis and assessment of risk. <i>Canadian Journal of Cardiology</i> , 2004, 20, 31-40.	1.7	38
31	Concomitant Digoxin Toxicity and Warfarin Interaction in a Patient Receiving Clarithromycin. <i>Annals of Pharmacotherapy</i> , 1999, 33, 796-799.	1.9	37
32	Elevated Adrenaline and Increased α_1 -Adrenoceptor-Mediated Vasoconstriction in Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1982, 4, S134-S138.	1.9	34
33	Use of Calcium Antagonists as Monotherapy in the Management of Hypertension. <i>American Journal of Medicine</i> , 1984, 77, 11-15.	1.5	34
34	Effects of prazosin in patients with hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 20, 138-141.	4.7	33
35	Fura-2 used as a probe to show elevated intracellular free calcium in platelets of Dahl-sensitive rats fed a high salt diet. <i>Biochemical and Biophysical Research Communications</i> , 1988, 154, 380-386.	2.1	33
36	Position of Calcium Antagonists in Antihypertensive Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, S21-S27.	1.9	32

#	ARTICLE	IF	CITATIONS
37	The Effects of Posture Change and Continuous Positive Airway Pressure on Cardiac Natriuretic Peptides in Congestive Heart Failure. <i>Chest</i> , 1995, 107, 909-915.	0.8	27
38	The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. <i>Canadian Journal of Cardiology</i> , 2002, 18, 604-24.	1.7	25
39	Calcium antagonism--A New concept for treating essential hypertension. <i>American Journal of Cardiology</i> , 1986, 57, D50-D53.	1.6	23
40	Effects of the Beta-Adrenoceptor-Blocking Agent Sotalol on Ventricular Arrhythmias in Patients with Chronic Ischemic Heart Disease. <i>Cardiology</i> , 1983, 70, 114-121.	1.4	22
41	Modulation of left ventricular hypertrophy by dietary salt and inhibition of angiotensin converting enzyme. <i>Journal of Hypertension</i> , 1988, 6, S145-147.	0.5	17
42	Masked hypertension: A common but insidious presentation of hypertension. <i>Canadian Journal of Cardiology</i> , 2006, 22, 617-620.	1.7	16
43	Serum Lipid Profile Determines Platelet Reactivity to Native and Modified LDL-Cholesterol in Humans. <i>Thrombosis and Haemostasis</i> , 1994, 71, 627-632.	3.4	14
44	Ticrynafen: Kinetics, protein binding, and effects on serum and urinary uric acid. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 23, 697-702.	4.7	13
45	Role of α -Adrenoceptor-Mediated Vasoconstriction for Antihypertensive β -Blockade. <i>Journal of Cardiovascular Pharmacology</i> , 1982, 4, S162-S167.	1.9	12
46	Temperature-dependence of LDL binding and activation of human platelets. <i>Thrombosis Research</i> , 1991, 64, 503-508.	1.7	12
47	Changing Role of Beta- and Alpha-Adrenoreceptor-Mediated Cardiovascular Responses in the Transition from High-Cardiac Output into a High-Peripheral Resistance Phase in Essential Hypertension. , 1981, , 316-326.		12
48	Applying the 2005 Canadian Hypertension Education Program recommendations: 1. Diagnosis of hypertension. <i>Cmaj</i> , 2005, 173, 480-483.	2.0	9
49	High normal blood pressure and prehypertension: The debate continues. <i>Canadian Journal of Cardiology</i> , 2007, 23, 581-583.	1.7	9
50	Smoking, Antihypertensive Treatment Benefit, and Comprehensive Antihypertensive Treatment Approach. <i>Journal of Cardiovascular Pharmacology</i> , 1990, 16, S77-S80.	1.9	9
51	The adrenaline α -adrenoceptor-mediated vasoconstrictor axis. <i>Clinical Science</i> , 1985, 68, 141s-146s.	0.0	8
52	Hemodynamic and Antihypertensive Treatment Responses with Calcium Antagonists. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, S126-S130.	1.9	7
53	Treatment of dyslipidemia: The problem of reaching the goal. <i>Atherosclerosis</i> , 2014, 236, 142-143.	0.8	7
54	Treatment Resistant Hypertension. <i>American Journal of Therapeutics</i> , 2008, 15, 351-355.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Do Recommendations for the Management of Hypertension Improve Cardiovascular Outcome? The Canadian Experience. <i>International Journal of Hypertension</i> , 2011, 2011, 1-3.	1.3	5
56	The question of the role of ethnicity on cardiovascular risk: does it matter where we come from?. <i>Journal of Hypertension</i> , 2005, 23, 1331-1333.	0.5	4
57	Targeting Hypertension in Patients with Cardiorenal Metabolic Syndrome. <i>Current Hypertension Reports</i> , 2012, 14, 397-402.	3.5	4
58	MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): A Review & Study Protocol. <i>Current Hypertension Reports</i> , 2015, 17, 533.	3.5	4
59	Sympathetic Nervous System in Essential Hypertension and Antihypertensive Response to β -Adrenoceptor Stimulation. <i>Journal of Cardiovascular Pharmacology</i> , 1984, 6, S753-5756.	1.9	2
60	Verapamil-induced vasodilator response is enhanced in essential hypertension. <i>General Pharmacology</i> , 1983, 14, 185-188.	0.7	1
61	Antihypertensive treatment in patients with cerebrovascular disease: the lower the better?. <i>Journal of Hypertension</i> , 2010, 28, 1380-1381.	0.5	1
62	Adrenaline and Enhanced Vasoconstriction in Patients with Essential Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1988, 63, 41-44.	0.0	0
63	Ischemic ECG changes are found more often in asymptomatic men with a coronary prone behaviour pattern. <i>Journal of Psychosomatic Research</i> , 1993, 37, 355-360.	2.6	0
64	Reducing Cardiovascular Risk with HMG CoA Reductase Inhibitors, Potential Contribution from Platelets. <i>Progress in Experimental Cardiology</i> , 2003, , 107-118.	0.0	0